Marker Shows Agressiveness of Squamous Cell Lesions

Laminin-5, Gamma-2 Chain Antibody can be used to differentiate those squamous cell lesions with a high risk of progression from those lesions with a low risk of progression, thereby improving the diagnosis of patients. This is the first antibody to label expression of the laminin-5, gamma-2 chain protein in squamous cell lesions with a high risk of developing invasive growth.

The new marker is a useful adjunct to the existing panel of antibodies used for the testing of squamous cell neoplasia within the cervix, ano-genital, and head and neck regions. The antibody is the product of DakoCytomation (Copenhagen, Denmark), an in vitro diagnostic company specializing in the identification of cancer markers on tissue samples obtained from biopsies and surgery.




Related Links:
DakoCytomation